Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 3/2003

01-03-2003 | Review Article

Optimizing bone metabolism in osteoporosis: insight into the pharmacologic profile of strontium ranelate

Author: P. J. Marie

Published in: Osteoporosis International | Special Issue 3/2003

Login to get access

Abstract

Strontium ranelate (SR) is currently being developed for the treatment of osteoporosis. Pharmacologic studies in animal models have shown that its efficacy on bone mass is based on its original mode of action on bone formation and bone resorption. In normal mice, SR increased bone formation and vertebral bone mass. In normal rats, SR increased bone mass and the mechanical properties of vertebral, humeral and femoral bones, associated with increased femoral shaft diameter. Vertebral bone mineral density and bone strength were also increased by SR, whereas stiffness was not altered, underlining that the improvement in bone strength occurs without inducing defective bone mineralization. In normal adult monkey alveolar bone, SR decreased bone resorption and increased bone. In ovariectomized (OVX) rats, SR limited the reduction in bone mineral content and the decrease in trabecular bone volume induced by estrogen deficiency, by inhibiting bone resorption while maintaining bone formation. Curative treatment with SR also partially restored bone mass in OVX rats. In the model of hind limb immobilization in rats, SR reduced bone resorption and partially limited long bone loss, as assessed by bone mineral content, bone volume, and histomorphometric and biochemical indices of bone resorption. The unique mode of action of SR on bone formation and resorption is also supported by in vitro studies. In calvaria culture systems and osteoblastic cell cultures, SR enhanced the replication of preosteoblastic cells and consequently increased collagen synthesis. Moreover, SR inhibited the bone-resorbing activity of isolated mouse osteoclasts and devreased osteoclast differentiation markers in chicken bone marrow cultures. Altogether, these pharmacologic results suggest that SR optimizes bone metabolism by decreasing bone resorption and promoting bone formation, which may be of potential value in the treatment of osteoporosis.
Literature
1.
Marie PJ. Effects of strontium on bone formation and bone cells. In: Neve J, Chappuis P, Lamand M, editors. Therapeutic uses of traces elements. New York: Plenum Press, 1996:277–82.
2.
Marie PJ, Ammann P, Boivin G, Rey C. Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int 2001;69:121–9.PubMed
3.
Delannoy P, Bazot D, Marie PJ. Long-term treatment with strontium ranelate increases vertebral bone mass without deleterious effect in mice. Metabolism 2002;51:906–11.
4.
Arlot ME, Roux JP, Boivin G, Perrat B, Tsouderos Y, Deloffre P, Meunier PJ. Effects of a strontium salt (S12911) on both tibial metaphysis and epiphysis in normal growing rats. J Bone Miner Res 1995;10(Suppl 1):356.
5.
Ammann P, Robin B, Bonjour JP, Tupinon-Mathieu I, Meyer JM, Rizzoli R. Long-term exposure to strontium ranelate dose-dependently increases bone strength in intact female rats [abstract]. Bone 2001;5(Suppl):S220.
6.
Ammann P, Rizzoli R, Deloffre P, Tsouderos Y, Meyer JM, Bonjour JP. Long-term administration of a high dose of the strontium salt S12911 has no toxic effect on bone biomechanics in female rats and may improve bone strength of the midshaft humerus. J Bone Miner Res 1995;10(Suppl 1):358.
7.
Buehler J, Chappuis P, Saffar JL, Tsouderos Y, Vignery A. Strontium ranelate inhibits bone resorption while maintaining bone formation in alveolar bone in monkeys (Macaca fascicularis). Bone 2001;29:176–9.CrossRefPubMed
8.
Shen V, Liu C, Marque V, Dupin-Roger I, Bazot D, Tupinon-Mathieu I. Histomorphometric evaluation of the tibiofibular junction after a long-term oral administration of S12911 in female rats. Bone Miner Res 2001;17(Suppl 1):375
9.
Ammann P, Robin B, Bonjour JP, Tupinon-Mathieu I, Meyer JM, Rizzoli R. Long-term exposure to strontium ranelate dose-dependently increases bone strength in intact female rats [abstract]. Bone 2001;5(Suppl);S220.
10.
Marie PJ, Hott M, Modrowski D, de Pollak C, Guillemain J, Deloffre P, et al. An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res 1993;8:607–15.PubMed
11.
Arlot ME, Braillon P, Roux JP, Deloffre P, Tsouderos Y, Meunier PJ. A new agent containing strontium (S12911) has a protective effect on bone loss in ovariectomized rats [abstract]. Bone 1992;13:A1.PubMed
12.
Marie PJ, Hott M, Modrowski D, Chappuis P, Guillemain J, Deloffre P, Tsouderos Y. S12911, a new agent containing strontium, inhibits bone loss due to immobilization in rats. J Bone Miner Res 1995;10(Suppl 1):165.
13.
Su Y, Bonnet J, Deloffre P, Tsouderos Y, Baron R. The strontium salt S12911 inhibits bone resorption in mouse calvaria and isolated rat osteoclast cultures. Bone Miner 1992;17(Suppl 1):188.
14.
Takahashi N, Sasaki T, Tsouderos Y, Suda T. Strontium ranelate inhibits osteoclastic bone resorption in vitro. J Bone Miner Res (submitted).
15.
Baron R, Tsouderos Y. In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation. Eur J Pharmacol 2002;450:11–7.
16.
Canalis E, Hott M, Deloffre P, Tsouderos Y, Marie PJ. The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone 1996;18:517–23.CrossRefPubMed
Metadata
Title
Optimizing bone metabolism in osteoporosis: insight into the pharmacologic profile of strontium ranelate
Author
P. J. Marie
Publication date
01-03-2003
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue Special Issue 3/2003
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-002-1344-5

Other articles of this Special Issue 3/2003

Osteoporosis International 3/2003 Go to the issue

Review Article

Bone matrix proteins: their function, regulation, and relationship to osteoporosis

Review Article

Reduced bone formation and increased bone resorption: rational targets for the treatment of osteoporosis

Review Article

Assessment of prevalent and incident vertebral fractures in osteoporosis research

Review Article

The mineralization of bone tissue: a forgotten dimension in osteoporosis research

Review Article

Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studies

Review Article

Is the calcium receptor a molecular target for the actions of strontium on bone?